Antischizophrenic activity independent of dopamine D2 blockade

Expert Opinion on Therapeutic Targets

Volumn 6, Issue 5, 2002, Pages 571-582

  Kalkman, Hans O ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

AMPA; GABA; Lamotrigine; NMDA; Schizophrenia

Indexed keywords

4 (3 PHOSPHONOALLYL) 2 PIPERAZINECARBOXYLIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; 4 PHOSPHONOMETHYLPIPECOLIC ACID; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; APTIGANEL; CALCIUM BINDING PROTEIN; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; CLOZAPINE; DIZOCILPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; EGLUMETAD; G PROTEIN COUPLED RECEPTOR; GLUTAMATE RECEPTOR; GLUTATHIONE; GLYCINE RECEPTOR ANTAGONIST; KETAMINE; KYNURENIC ACID; LAMOTRIGINE; METABOTROPIC RECEPTOR; N ACETYLASPARTYLGLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OLANZAPINE; PHENCYCLIDINE; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; UNINDEXED DRUG;

COGNITIVE DEFECT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING SITE; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG MECHANISM; ENVIRONMENTAL FACTOR; GENETIC LINKAGE; HUMAN; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SYMPTOMATOLOGY;

AMINO ACID TRANSPORT SYSTEM X-AG; ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN CHEMISTRY; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; FRONTAL LOBE; GLUTAMATE PLASMA MEMBRANE TRANSPORT PROTEINS; GLUTAMIC ACID; HUMANS; INTERNEURONS; KETAMINE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RATS; RECEPTORS, AMPA; RECEPTORS, DOPAMINE D2; RECEPTORS, GABA; RECEPTORS, GLUTAMATE; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, NEUROTRANSMITTER; SCHIZOPHRENIA; SYMPORTERS; TRIAZINES;

EID: 0036398481     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.6.5.571     Document Type: Review

References (123)

1. LEUCHT S, PITSCHEL-WALZ G, ABRAHAM D, KISSLING W: Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res. (1999) 35:51-68.
2. TSUANG M: Schizophrenia: genes and environment. Biol. Psychiatry (2000) 47:210-220.
3. CROW T: Current status of linkage for schizophrenia: polygenes of vanishingly small effect or multiple false positives? Am. J. Med. Genet. (1997) 74:99-103.
4. TSUANG M, FARAONE SV: The frustrating search for schizophrenia genes. Am. J. Med. Genet. (2000) 97:1-3.
5. KARAYIORGOU M, GOGOS JA: A turning point in schizophrenia genetics. Neuron (1997) 19:967-979.
6. SCHAEFER CA, BROWN AS, WYATT RJ et al.: Maternal prepregnant body mass and risk of schizophrenia in adult offspring. Schizophr. Bull. (2000) 26:275-286.
7. MALASPINA D, HARLAP S, FENNIG S et al.: Advancing paternal age and the risk of schizophrenia. Arch. Gen. Psychiatry (2001) 58:361-367.
8. KARLSSON H, BACHMANN S, SCHRÖDER J et al.: Retroviral RNA identified in the cerebral fluids and brains of individuals with schizophrenia. Proc. Natl. Acad. Sci. USA (2001) 98:4634-4639.
9. BROWN AS, SCHAEFFER CA, WYATT RJ et al.: Maternal exposure to respiratory infections and adult schizophrenia spectrum disorders: a prospective birth cohort study. Schizophr. Bull. (2000) 26:287-295.
10. MCNEIL TF, CANTOR-GRAAE E, WEINBERGER DR: Relationship of obstetric complications and differences in size of brain structures in monozygotic twin pairs discordant for schizophrenia. Am. J. Psychiatry (2000) 157:203-212.
11. TORREY EF, MILLER J, RAWLING R, YOLKEN RH: Seasonality of births in schizophrenia and bipolar disorder: a review of the literature. Schizophr. Res. (1997) 28:1-38.
12. EATON WW, MORTENSON PB, FRYDENBERG M: Obstetric factors, urbanization and psychosis. Schizophr. Res. (2000) 43:117-123.
13. WEINBERGER DR: From neuropathology to neurodevelopment. Lancet (1995) 346:552-557.
14. WOODS BT. Is schizophrenia a progressive neurodevelopmental disorder? Towards a unitary pathogenic mechanism. Am. J. Psychiatry (1998) 155:1661-1670.
15. FEINBERG I: Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? J. Psychiatr. Res. (1982/ 1983) 17:319-334.
16. LEWIS DA: Development of the prefrontal cortex during adolescence: insights into vulnerable neural circuits in schizophrenia. Neuropsychopharmacology (1997) 16:385-398.
17. WRIGHT IC, RABE-HESKETH S, WOODRUFF PWR et al.: Meta-analysis of regional brain volumes in schizophrenia. Am. J. Psychiatry (2000) 157:16-25.
18. SHENTON ME, DICKEY CC, FRUMIN M, MCCARLEY RW: A review of MRI findings in schizophrenia. Schizophr. Res. (2001) 49:1-52.
19. LAWRIE SM, WHALLEY HC, ABUKMEIL SS et al.: Brain structure, genetic liability, and psychotic symptoms in subjects at high risk of developing schizophrenia. Biol. Psychiatry (2001) 49:811-823.
20. HARRISON PJ: The neuropathology of schizophrenia: a critical review of the data and their interpretation. Brain (1999) 122:593-624.
21. GLANTZ LA, LEWIS DA: Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch. Gen. Psychiatry (2000) 57:65-73.
22. MIRNICKS K, MIDDLETON FA, MARQUEZ A et al. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron (2000) 28:53-67.
23. MIDDLETON FA, MIRNICKS K, PIERRI JN et al. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia J Neurosci. (2002) 22:2718-2729.
24. VAWTER MP, BARRETT T, CHEADLE C et al. Application of cDNA microarrays to examine gene expression differences in schizophrenia. Brain Res. Bull. (2001) 55:641-650.
25. HAKAK Y. WALKER JR, LI C et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl. Acad Sci. USA (2001) 98:4746-4751.
26. MELDRUM BS: Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J. Nutr. (2000) 130:1007S-1015S.
27. CONN PJ, PIN JP: Pharmacology and functions of metabotropic glutamate receptors. Ann. Rev. Pharmacol. Toxicol. (1997) 37:205-237.
28. HAWKINS LM, CHAZOT PL, STEPHENSON FA: Biochemical evidence for the co-association of three N-methyl-D-aspartate (NMDA) R2 subunits in recombinant NMDA receptors. J Biol. Chem. (1999) 274:27211-27218.
29. DINGLEDINE R, BORGES K, BOWIE D, TRAYNELIS SF: The glutamate receptor ion channels. Pharmacol. Rev. (1999) 51:8-61.
30. LAUBE B, HIROKAZU H, BETZ H, KUHSE J: Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit. Neuron (1997) 18:493-503.
31. ANSON LC, CHEN PE, WYLLIE DJ et al. Identification of amino acid residues of the NR2A subunit that control glutamate potency in recombinant NRI/NR2A NMDA receptors. J. Neurosci. (1998) 18:581-589.
32. HIRAI H, KIRSCH J, LAUBE B et al. The glycine binding site of the N-methyl-D-aspartate receptor subunit NR1: identification of novel determinants of co-agonist potentiation in the extracellular M3-M4 loop region. Proc. Natl. Acad. Sei. USA (1996) 93:6031-6036.
33. 2+ permeability of KA-AMPA-gated glutamate receptor channels depends on subunit composition. Science (1991) 252:851-853.
34. A receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol. Sci. (2001) 22:188-194.
35. MÖHLER H, FRITSCHY JM, RUDOLPH U: A new benzodiazepine pharmacology. J PharmacoL Exp. Ther. (2002) 300:2-8.
36. MAEDOR-WOODRUFF JH, HEALY DJ: Glutamate expression in schizophrenic brain. Brain Res. Rev. (2000) 31:288-294.
37. PIERRI JN, CHAUDRY AS, WOO TU, LEWIS DA: Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. Am. J. Psychiatry (1999) 156:1709-1719.
38. A receptor α-1 subunit messenger RNA and human GABA transporter-1 (HGAT-1) messenger RNA expression. Neuroscience (1999) 93:441-448.
39. VOLK DW. AUSTIN MC, PIERRI JN et al. GABA transporter-1 in RNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons. Am. J. Psychiatry (2001) 158:256-265.
40. 67 messenger RNA expression in a subset of prefrontal cortical Υ-aminobutyric acid neurons in subjects with schizophrenia. Arch. Gen. Psychiatry (2000) 57:237-245.
41. 67) expression in schizophrenia and bipolar disorder. Arch. Gen. Psychiatry (2000) 57:1061-1069.
42. IMPAGNATIELLO F, GUIDOTTI AR, PESOLD C et al. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc. Natl. Acad Sci. USA (1998) 95:15718-15723.
43. FATEMI SH, EARLE JA, MCMENOMY T. Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression. Mol. Psychiatry (2000) 5:654-663.
44. DANOS P, BAUMANN B, BERNSTEIN HG et al. Schizophrenia and anteroventral thalamic nucleus: selective decrease of parvalburnin-immunoreactive thalamocortical projection neurons. Psychiatry Res. (1998) 82:1-10.
45. LEWIS DA, CRUZ DA, MELCHITZKY DS, PIERRI JN: Lamina-specific deficits in parvalbumin-immunoreactive varicosities in the prefrontal cortex of subjects with schizophrenia: evidence for fewer projections from the thalamus. Am. J. Psychiatry (2001)
46. REYNOLDS GP, ZHANG ZJ, BEASLEY CL: Neurochemical correlates of cortical GABAergic deficits in schizophrenia: selective losses of calcium binding protein immunoreactivity. Brain Res. Bull. (2001) 55:579-584.
47. 2+ rises and consequent oxygen radical production. J. Neurosci. (1998) 18:7727-7738.
48. DEUTSCH SI, ROSSE RB, SCHWARTZ B, MASTROPAOLO J: A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin. Neuropharmacol. (2001) 24:43-49.
49. LEWIS DA, LIEBERMAN JA: Catching up on schizophrenia: natural history and neurology. Neuron (2000) 28:325-334.
50. +)- permeable AMPA receptors by joro spider toxin in cultured rat hippocampal neurones. J Physiol. (1996) 496:431-437.
51. 2+-permeable AMPA/kainate channels display distinct receptor immunoreactivity and are GABAergic. Neurobiol Dis. (1994) 1:43-49.
52. ZHANG ZJ, REYNOLDS GP: A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia. Schizophr. Res. (2002) 55:1-10.
53. MOGA D, HOF PR, VISSAVAJJHALA P et al. Parvalbumin-containing interneurons in rat hippocampus have an AMPA receptor profile suggestive of vulnerability to excitotoxicity. J Chem. Neuroanat. (2002) 23:249-253.
54. DEAKIN JF, SIMPSON MD: A two process theory of schizophrenia: evidence from studies in post-mortem brain. J Pychiatr. Res. (1997) 31:277-295.
55. PIERRI JN, VOLK CLE, AUH S et al. Decreased somal size of deep layer 3 pyramidal neurons in prefrontal cortex of subjects with schizophrenia. Arch. Gen. Psychiatry (2001) 58:466-473.
56. LUBY ED, COHEN BD, ROSENBAUM G, GOTTLIEB JS, KELLEY R: Study of a new schizophrenomimetic drug - Sernyl. Arch. Neurol. Pychiatry (1959) 81:363-369.
57. DOMINO EF, CHODOFF P, CORSSEN G: Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin. Pharmacol. Ther. (1965) 6:279-291.
58. KRYSTAL JH, KARPER LP, SEIBYL JP et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neumendocrine responses. Arch. Gen. Psychiatry (1994) 51:199-214.
59. MALHOTRA AK, PINALS DA, WEINGARTNER H et al. NMDA receptor function and human cognition: the effects of ketamine in healthy subjects. Neuropsychopharmacology (1996) 14:301-308.
60. MUIR KW, GROSSET DG, LEES KR: Effects of prolonged infusions of the NMDA antagonist aptiganel hydrochloride (CNS 1102) in normal volunteers. Clin. Neuropharmacology (1997) 20:311-321.
61. KRISTENSEN JD, SVENSSON B, GORDH T.- The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans. Pain (1992) 51:249-253.
62. HERRLING P: D-CPPene (SDZ EAA 494), a competitive NMDA antagonist. Results from animal models and first results in humans. Neuropsychopharmacol. (1994) 10:591.
63. GROTTA J, CLARK W, COULL B et al. Safety and tolerability of the glutamate antagonist CGS 19755 (selfotel) in patients with acute ischemic stroke. Results of a Phase IIa randomized trial. Stroke (1995) 26:602-605.
64. ADLER CM, MALHOTRA AK, ELMAN I et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am. J Psychiatry (1999) 156:1646-1649.
65. NEWCOMER JW, FARBER NB, JECTOVIC-TODOROVIC V et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neurapsychopharmacology (1999) 20:106-118.
66. UMBRICHT D, SCHMID L, KOLLER R et al. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers. Arch. Gen. Psychiatry (2000) 57:1139-1147.
67. LAHTI AC, WEILER M, MICHAELIDIS T et al. Effects of ketamine in normal and schizophrenic volunteers. Neuropsycbopharmacology (2001) 25:455-467.
68. KIM JS, KORNHUBER HH, SCHMID-BURKE W, HOLZMÜLLER B: Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis of schizophrenia. Neurosci. Lett. (1980) 20:379-382.
69. TORU M, KURAMAJI A, KUMASHIRO S et al. Excitatory amino acidergic neurones in chronic schizophrenic brain. Mol Neuropharmacol. (1992) 2:241-243.
70. DO KQ, LAUER CJ, SCHREIBER W, ZOLLINGER M etal. γ- Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. (1995) 65:2652-2662.
71. TSAI G, VAN KAMMEN DP, CHEN S et al. Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. Biol Psychiatry (1998) 44:667-674.
72. FAUSTMAN WO, BARDGETT M, FAULL KF et al. Cerebrospinal fluid glutamate inversely correlates with positive symptom severity in unmedicated male schizophrenic/schizoaffective patients. Biol Psychiatry (1999) 45:68-75.
73. DAVIS KL, KAHN RS, KO G, DAVIDSON M: Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry (1991) 148:1474-1486.
74. SCHWARCZ R, RASSOULPOUR A, WU HQ et al. Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry (2001) 50:521-530.
75. ERHARDT S, BLENNOW K, NORDIN C et al. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci. Lett. (2001) 313:96-98.
76. WROBLEWSKA B, WROBLEWSKA JT, PSHENICHKIN S et al. N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J Neurochem. (1997) 69:174-181.
77. 3H] norepinephrine release from rat hippocampal slides. J. Pharmacol Exp. Ther. (1993) 266:796-803.
78. GRUNZE HC, RAINNIE DG, HASSELMO ME et al. NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci. (1996) 16:2034-2043.
79. TSAI G, PASSANI LA, SLUSHERBS et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiatry (1995) 52:829-836.
80. KÖHR G, ECKARDT S, LUDDENS H, MONYER H et al. NMDA receptor channels: subunit-specific potentiation by reducing agents. Neuron (1994) 12:1031-1040.
81. PAOLETTI P, ASCHER P, NEYTON J: High-affinity Zn inhibition of NMDA, NR1-NR2A receptors. J. Neurosci. (1997) 17:5711-5725.
82. DO KQ, TRABENSINGER AH, KIRSTEN-KRÜGER M et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci. (2000) 12:3721-3728.
83. MOGHADDAM B, ADAMS B, VERMA A, DALY D: Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. (1997) 17:2921-2927.
84. MATHÉ JM, NOMIKOS G, SCHILSTRÖM B, SVENSSON TH: Non-NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemic dizocilpine (MK-801) induced hyperlocomotion and dopamine release in the nucleus accumbens. J Neurosci. Res. (1998) 51:583-592.
85. OLNEY JW, LABRUYERE J, PRICE MT: Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science (1989) 244:1360-1362.
86. SHARP FR, TOMITAKA M, BERNAUDIN M, TOMITAKA S: Psychosis: Pathological activation of limbic thalamocortical circuits by psychotomimetics and schizophrenia? Trends Neurosci. (2001) 24:330-334.
87. SHARP JW, PETERSEN DL, LANGFORD MT DNQX inhibits phencyclidine (PCP) and ketamine induction of the hsp70 heat shock gene in rat cingulate, and retrospinal cortex. Brain Res. (1995) 687:114-124.
88. TOMITAKA S, TOMITAKA M, TOLLIVER BK, SHARP FR: Bilateral blockade of NMDA receptors in anterior thalamus by dizocilpine (MK-801) injures pyramidal neurons in the rat retrospinal cortex. Eur. J Neurosci. (2000) 12:1420-1430.
89. FARBER NB, KIM SH, DIKRANIAN K et al. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol. Psychiatry (2002) 7:32-43.
90. MOGHADDAM B, ADAMS B: Reversal of phencyclidine effects by group II metabotropic glutamate receptor agonist in rats. Science (1998) 281:1349-1352.
91. WANG SJ, SIHRA TS, GEAN PW: Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity. NeuroReport (2001) 12:2255-2258.
92. CUNNINGHAM MO, JONES RS: The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology (2000) 39:2139-2146.
93. ANAND A, CHARNEY DS, OREN DA et al. Attenuation of neuropsychiatric effects of ketamine with lamotrigine. Arch. Gen. Psychiatry (2000) 57:270-276.
94. DURSUN SM, MCINTOSH D, MILLIKEN H: Clozapine plus lamotrigine in treatment-resistant schizophrenia. Arch. Gen. Psychiatry (1999) 56:950.
95. DURSUN SM, DEAKIN JF: Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J. Pychopharmacol. (2001) 15:297-301.
96. DRAPALSKI AL, ROSSE RB, PEEBLES RR et al. Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication. Clin. Neuropharmacol. (2001) 24:290-294.
97. LIPSKA BK, WEINBERGER DR: To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology (2000) 23:223-229.
98. PEARCE BD: Schizophrenia and viral infection during neurodevelopment: a focus on mechanisms. Mol. Psychiatry (2001) 6:634-646.
99. MALLARD EC, REHN A, REES S et al. Ventriculomegaly and reduced hippocampal volume following intrauterine growth-restriction: implications for the aetiology of schizophrenia. Schizophr. Res. (1999) 40:11-21.
100. FATEMI SH, CUADRA AE, ELFAKAHANY EE et al. Prenatal viral infection causes alterations in nNOS expression in developing mouse brains. NeuroReport (2000) 11:1493-1496.
101. PLETNIKOV MV, RUBIN SA, VASUDEVAN K, MORAN TH et al. Developmental brain injury associated with abnormal play behavior in neonatally Borna disease virus-infected Lewis rats: a model of autism. Behav. Brain. Res. (1999) 100:43-50.
102. PEARCE BD, VALADI NM, PO CL, MILLER AH: Viral infections of developing GABAergic neurons in a model of hippocampal disinhibition. NeuroReport (2000) 11:2433-2438.
103. NUSSER Z, SIEGHART W, BENKE D et al. Differential synaptic localization of two major γ-aminobutyric acid type A receptor α subunits on hippocampal pyramidal cells. Proc. Natl. Acad. Sci. USA (1996) 93:11939-11944.
104. FRITSCHY JM, WEINMANN O, WENZEL A, BENKE D: Synapse-specific localization of NMDA and GABA(A) receptor subunits revealed by antigen-retrieval immunohistochemistry. J Comp. Neurol. (1998) 390:194-210.
105. 2+, permeable AMPA or kainate receptors: possible key factors in selective neurodegeneration. Trends Neurosci. (2000) 23:365-371.
106. KRUPITSKY EM, BURAKOV AM, ROMANOVA TN et al. Attenuation of ketamine effects by nimodipine pretreatment in recovering ethanol dependent men: psychopharmacologic implications of the interaction of NMDA and L-type calcium channel antagonists. Neuropsychopharmacology (2001) 25:936-947.
107. YAMADA K, KANBA S, ASHIKARI I et al. Nilvadipine is effective for chronic schizophrenia. J. Clin. Psychopharmacol (1996) 16:437-439.
108. KNOLL IV JL, GARVER DL, RAMBERG JE et al. Heterogeneity of the psychoses: is there a neurodegenerative psychosis? Schizophr. Bull. (1998) 24:365-379.
109. DAVIS KL, BUCHSBAUM MS, SHIHABUDDIN L et al. Ventricular enlargement in poor-outcome schizophrenia. Biol. Pychiatry (1998) 43:783-793.
110. JOHNSON KM, PHILLIPS M, WANG C, KEVETTER GA: Chronic phencyclidine induces behavioural sensitisation and apoptotic cell death in the olfactory and piriform cortex. J Neurosci. Res. (1998) 52:709-722.
111. MITCHELL I, COOPER AJ, GRIFFITHS MR, BARBER DJ: Phencyclidine and corticosteroids induce apoptosis of a subpopulation of striatal neurones: a neural substrate for psychosis. Neurosci. (1998) 84:489-501.
112. CEPEDA C, RADISAVLJEVIC Z, PEACOCK W et al. Differential modification by dopamine of responses evoked by excitatory amino acids in human cortex. Synapse (1992) 11:330-341.
113. HENZE DA, GONZALES-BORGOS GR, URBAN NN, LEWIS DA et al. Dopamine increases excitability of pyramidal neurons in primate prefrontal cortex. J Neurophysiol. (2000) 84:2799-2809.
114. WILLIAMS GV, GOLDMAN-RAKIC PS: Modulation of memory fields by dopamine D1 receptors in the prefrontal cortex. Nature (1995) 376:572-575.
115. SEAMANS JK, FLORESCO SB, PHILLIPS AG: D1 receptor modulation of hippocampal-prefrontal cortical circuits integrating spatial memory with executive functions in the rat. J. Neurosci. (1998) 18:1613-1621.
116. ZHENG P, ZHANG XX, BUNNEY BS, SHI WX: Opposite modulation of cortical N-methyl-D-aspartate receptor-mediated responses by low and high concentrations of dopamine. Neuroscience (1999) 91:527-535.
117. SEAMANS JK, DURSTEWITZ D, CHRISTIE BR et al. Dopamine D1/D5 receptor modulation of excitatory synaptic inputs to layer V prefrontal cortex neurons. Proc. Natl. Acad. Sci. USA (2001) 98:301-306.
118. STEELE TD, HODGES DB, LEVESQUE TR et al. D1 agonist dihydrexidine releases acetylcholine and improves cognititive performance in rats. Pharmacol. Biochem. Behav. (1997) 58:477-483.
119. CAI JX, ARNSTEN AF: Dose-dependent effects of the dopamine D1 receptor agonists A77636 or SKF81297 on spatial working memory in aged monkeys. J. Pharmacol. Exp. Tber. (1997) 283:183-189.
120. OKUBO Y, SUHARA T, SUZUKI K et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature (1997) 385:634-636.
121. CHIODO LA, BANNON MJ, GRACE AA et al. Evidence for the absence of impulse-regulating somatodendritic and synthesis-modulating nerve terminal autoreceptors on subpopulations of mesocortical dopamine neurons. Neuroscience (1984) 12:1-16.
122. SESACK SR, HAWRYLAK VA, MATUS C et al. Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci. (1998) 18:2697-2708.
123. LEWIS DA, MELCHITZKY DS, SESACK SR et al. Dopamine transporter immunoreactivity in monkey cerebral cortex. J Comp. Neurol. (2001) 432:119-136.